Intech Investment Management LLC Acquires 22,254 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Intech Investment Management LLC boosted its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 61.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 58,242 shares of the biotechnology company’s stock after buying an additional 22,254 shares during the quarter. Intech Investment Management LLC’s holdings in Heron Therapeutics were worth $89,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Anfield Capital Management LLC grew its position in shares of Heron Therapeutics by 5.6% during the 4th quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 6,264 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Heron Therapeutics by 0.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company’s stock valued at $1,692,000 after purchasing an additional 9,418 shares during the period. Glenmede Trust Co. NA increased its position in Heron Therapeutics by 49.6% in the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock worth $63,000 after buying an additional 10,578 shares during the last quarter. Principal Financial Group Inc. increased its position in Heron Therapeutics by 10.6% in the fourth quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company’s stock worth $174,000 after buying an additional 10,909 shares during the last quarter. Finally, Zacks Investment Management raised its stake in shares of Heron Therapeutics by 2.4% in the third quarter. Zacks Investment Management now owns 475,575 shares of the biotechnology company’s stock valued at $946,000 after buying an additional 11,320 shares during the period. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Stock Performance

Shares of NASDAQ HRTX opened at $2.31 on Friday. The stock has a fifty day moving average of $1.99 and a 200-day moving average of $1.78. The stock has a market cap of $351.88 million, a PE ratio of -12.83 and a beta of 1.55. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.05. The company had revenue of $40.78 million for the quarter, compared to the consensus estimate of $37.37 million. On average, sell-side analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on HRTX shares. Needham & Company LLC restated a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, February 28th. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 8th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.